Skip to content

Study on the mechanism of local recurrence after ablation of liver tumors

Study on the mechanism of local recurrence after ablation of liver tumors

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121111
Enrollment
Unknown
Registered
2026-03-25
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

local tumor progression of hepatocellular carcinoma

Interventions

Primary hepatocellular carcinoma group:None
Local tumor progression group:None
Recurrent hepatocellular carcinoma group:None

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, WHO/ECOG physical status score =80g/L; PLT>=50×10^9/L; Coagulation function test: PT<20s.

Exclusion criteria

Exclusion criteria: 1. Unclear pathological results or incomplete clinical data; 2. Infection, cardiovascular and cerebrovascular diseases, liver, kidney and lung failure or other systemic malignant tumors with significant clinical symptoms. 3. History of unexplained bleeding, severe anemia, bleeding tendency, or uncorrected coagulation dysfunction; 4. Massive ascites; 5. Pregnant or lactating women; 6. Other factors that the investigators believe are not suitable for inclusion or affect the subject's participation in the study.

Design outcomes

Primary

MeasureTime frame
Nuclear rate;Cell activity;Composition and proportion of immune cell subsets;Cell-to-cell communication (ligand-receptor interaction) strength;Markers of tumor cell heterogeneity;Molecular expression at key immune checkpoints;

Countries

China

Contacts

Public ContactMing Xu

The First Affiliated Hospital,Sun Yat-sen University

xuming8@mail.sysu.edu.cn+86 20 87765183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026